TRASTUZUMAB REZETECAN

UNII:	1000BJC8CR
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	TRASTUZUMAB REZETECAN
GSRS Full Record:	1000BJC8CR i

2647845-11-0
Immunoglobulin G1, anti-(human epidermal growth factor receptor HER2) (human-Mus musculus monoclonal SHR-1805 γ1-chain), complex with human-Mus musculus monoclonal SHR-1805 κ-chain, dimer, thioether with N-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]glycylglycyl-L-phenylalanyl-N-[[(1R)-1-cyclopropyl-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-2-oxoethoxy]methyl]glycinamide
Trastuzumab Rezetecan
Trastuzumab rezetecan [WHO-DD]
immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody, conjugated via a cleavable linker with a camptothecin derivative
trastuzumab rezetecan [INN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

TRASTUZUMAB REZETECAN

Synonyms and Mappings

Resources